Genome-wide CRISPR screen identifies ESPL1 limits the response of gastric cancer cells to apatinib Cancer Cell International, 24 Feb 2024 Abstract Apatinib was the first anti-angiogenic agent approved for treatment of metastatic gastric cancer (GC).